Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B--Coinfected Adults.

MLA

Gallant, Joel, et al. “Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B--Coinfected Adults.” JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 73, no. 3, Nov. 2016, pp. 294–98. EBSCOhost, https://doi.org/10.1097/QAI.0000000000001069.

APA

Gallant, J., Brunetta, J., Crofoot, G., Benson, P., Mills, A., Brinson, C., Shinichi Oka, Cheng, A., Garner, W., Fordyce, M., Das, M., & McCallister, S. (2016). Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B--Coinfected Adults. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 73(3), 294–298. https://doi.org/10.1097/QAI.0000000000001069

Chicago

Gallant, Joel, Jason Brunetta, Gordon Crofoot, Paul Benson, Anthony Mills, Cynthia Brinson, Shinichi Oka, et al. 2016. “Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B--Coinfected Adults.” JAIDS: Journal of Acquired Immune Deficiency Syndromes 73 (3): 294–98. doi:10.1097/QAI.0000000000001069.